Deborah Chirnomas

1.3k total citations · 1 hit paper
18 papers, 898 citations indexed

About

Deborah Chirnomas is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Deborah Chirnomas has authored 18 papers receiving a total of 898 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Deborah Chirnomas's work include Acute Myeloid Leukemia Research (6 papers), Hemoglobinopathies and Related Disorders (4 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Deborah Chirnomas is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Hemoglobinopathies and Related Disorders (4 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Deborah Chirnomas collaborates with scholars based in United States, United Kingdom and Israel. Deborah Chirnomas's co-authors include Keith R. Hornberger, Craig M. Crews, Rosemary Foster, Toshiyasu Taniguchi, Jennifer Mahoney, Alan D. D’Andrea, Richard D. Kennedy, Ami Vaidya, Michael V. Seiden and Anne-Renee Hartman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Deborah Chirnomas

18 papers receiving 877 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Protein degraders enter the clinic — a new approach to cancer therapy

2023 375 citations Deborah Chirnomas, Keith R. Hornberger et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deborah Chirnomas United States	10	580	294	237	148	91	18	898
Justin M. Watts United States	17	560 1.0×	193 0.7×	530 2.2×	169 1.1×	26 0.3×	127	968
Magdalena Plašilová United States	12	372 0.6×	202 0.7×	329 1.4×	128 0.9×	42 0.5×	17	945
Monica Pallis United Kingdom	23	674 1.2×	509 1.7×	590 2.5×	168 1.1×	36 0.4×	61	1.3k
Renata Binato Brazil	19	532 0.9×	205 0.7×	109 0.5×	146 1.0×	22 0.2×	60	876
Matthew J. Saabye United States	8	267 0.5×	190 0.6×	116 0.5×	85 0.6×	36 0.4×	8	703
Marie Sébert France	13	281 0.5×	123 0.4×	313 1.3×	116 0.8×	24 0.3×	47	593
Shwu‐Luan Lee United States	6	353 0.6×	118 0.4×	219 0.9×	103 0.7×	18 0.2×	7	655
Laurie Feldman United States	16	303 0.5×	149 0.5×	320 1.4×	72 0.5×	155 1.7×	34	717
Jenny Ho Canada	10	274 0.5×	190 0.6×	134 0.6×	70 0.5×	46 0.5×	25	584

Countries citing papers authored by Deborah Chirnomas

Since Specialization

Citations

This map shows the geographic impact of Deborah Chirnomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Chirnomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Chirnomas more than expected).

Fields of papers citing papers by Deborah Chirnomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Chirnomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Chirnomas. The network helps show where Deborah Chirnomas may publish in the future.

Co-authorship network of co-authors of Deborah Chirnomas

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Chirnomas. A scholar is included among the top collaborators of Deborah Chirnomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Chirnomas. Deborah Chirnomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Tyrakis, Petros A., G Steele, Deborah Chirnomas, et al.. (2025). Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models. British Journal of Cancer. 133(2). 144–154. 2 indexed citations

Chirnomas, Deborah, Keith R. Hornberger, & Craig M. Crews. (2023). Protein degraders enter the clinic — a new approach to cancer therapy. Nature Reviews Clinical Oncology. 20(4). 265–278. 375 indexed citations breakdown →

Shore, Neal D., John Paul Shen, Michael Devitt, et al.. (2022). Phase 1b study of bavdegalutamide, an androgen receptor PROTACdegrader, combined with abiraterone in patients with metastatic prostate cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS5106–TPS5106. 7 indexed citations

Hamilton, Erika, Linda T. Vahdat, Hyo S. Han, et al.. (2022). Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer. Cancer Research. 82(4_Supplement). PD13–8. 47 indexed citations

Duncan, Christine, Andrew St. Martin, Waleska S. Pérez, et al.. (2021). Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation. Pediatric Blood & Cancer. 68(8). e29067–e29067. 3 indexed citations

Wang, Eunice S., Richard Aplenc, Deborah Chirnomas, et al.. (2020). Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 61(8). 1965–1973. 11 indexed citations

Ho, Vincent T., Andrew St. Martin, Waleska S. Pérez, et al.. (2019). Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation. 26(5). 884–892. 18 indexed citations

Wang, Eunice S., Richard Aplenc, Deborah Chirnomas, et al.. (2018). Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 132(Supplement 1). 3979–3979. 1 indexed citations

Duncan, Christine, Andrew St. Martin, Waleska S. Pérez, et al.. (2018). Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation. 24(3). S302–S302. 3 indexed citations

10.

Ho, Vincent T., Andrew St. Martin, Waleska S. Pérez, et al.. (2018). Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT). Biology of Blood and Marrow Transplantation. 24(3). S301–S302. 2 indexed citations

11.

Anderson, Sylvia L., Chaim Jalas, Anastasia Fedick, et al.. (2014). A founder mutation in the TCIRG1 gene causes osteopetrosis in the Ashkenazi Jewish population. Clinical Genetics. 88(1). 74–79. 7 indexed citations

12.

Goldberg, Stuart L., Patricia J. Giardina, Deborah Chirnomas, et al.. (2013). The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatric Blood & Cancer. 60(9). 1507–1512. 23 indexed citations

13.

Rienhoff, Hugh Young, Vip Viprakasit, Paul Harmatz, et al.. (2010). A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica. 96(4). 521–525. 33 indexed citations

14.

Chirnomas, Deborah, Aleksandra Yakhkind, Carole Paley, & Ellis J. Neufeld. (2010). Strategies to Improve Iron Chelation In Thalassemia Patients Poorly Responsive to Deferasirox:. Blood. 116(21). 4279–4279. 2 indexed citations

15.

Chirnomas, Deborah, Yaron Finkelstein, Luis M. Pereira, et al.. (2009). Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 114(19). 4009–4013. 75 indexed citations

16.

Pumbo, Elena, Jennifer Ivanovich, Ping An, et al.. (2008). TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood. 113(2). 309–316. 111 indexed citations

17.

Chirnomas, Deborah, Toshiyasu Taniguchi, Ami Vaidya, et al.. (2006). Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Molecular Cancer Therapeutics. 5(4). 952–961. 163 indexed citations

18.

Seefelder, Christian, et al.. (2005). Perioperative management of a child with severe hypertension from a catecholamine secreting neuroblastoma. Pediatric Anesthesia. 15(7). 606–610. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact